

27 May 2025

Futura Medical plc
("Futura" or the "Company")

Notice of AGM and availability of Annual Report

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, today announces its Annual General Meeting ("AGM") will be held at 10:00am on Thursday, 19 June 2025 at the offices of Panmure Liberum, Ropemaker Place, 25 Ropemaker Street, London EC2Y 9LY.

If you wish to attend the meeting in person, please register your interest, prior to 10:00am on Monday 16 June 2025, at investor.relations@futura-medical.com.

Shareholders are asked to cast their vote as follows: (1) casting your proxy vote online via the Investor Centre app or by accessing the web browser at <https://uk.investorcentre.mpms.mufg.com/> and following the instructions; or (2) in the case of CREST members, by utilising the CREST electronic proxy appointment service; or (3) if you are an institutional investor you may also be able to appoint a proxy electronically via the Proximity platform; or (4) requesting a hard copy form of proxy directly from the registrars, MUFG Corporate Markets. For further information, please refer to the notes to the Notice of Annual General Meeting. If you choose to attend the Annual General Meeting in person instead of appointing the Chairman of the meeting as proxy, you will still be able to vote in person at the Annual General Meeting.

If you are not attending the Annual General Meeting in person, your proxy vote will need to be logged by 10:00am on Tuesday 17 June 2025, as no online voting will take place in-real time during the meeting itself.

The Board will make arrangements for shareholders to listen to proceedings remotely should they wish to do so. You can request access by emailing: investor.relations@futura-medical.com prior to 10:00 a.m. on 16 June 2025. Shareholders will not get an opportunity to vote or ask questions or participate in any other way during the call.

Annual Report

Futura's annual report and accounts for the year ended 31 December 2024 (the "Annual Report") is available to shareholders as an electronic communication pursuant to the Companies Act 2006 and is now available on the Company's website www.futura-medical.com, along with the Notice of AGM.

Contacts:

Futura Medical plc	James Barder	investor.relations@futura-medical.com
	Chief Executive Officer	+44 (0)1483 685 670
	Angela Hildreth	www.futura-medical.com
	Finance Director and COO	
Panmure Liberum Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance)	+44 (0)20 3100 2000
	Rupert Dearden (Corporate Broking)	
Alma Strategic Communications	Rebecca Sanders-Hewett	+44 (0)20 3405 0205
	Sam Modlin	futura@almastrategic.com
	Will Ellis Hancock	

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAEXLFLEELZBBE